Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?

nork Desai, Mitesh, Wooller, Annette, Lignugaris, Arunas, Gopal, Srihari
Argitaratua izan da Psychol Med (2018)

Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse

nork Wang, Dai, Gopal, Srihari, Baker, Susan, Narayan, Vaibhav A.
Argitaratua izan da NPJ Schizophr (2018)

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?

nork Ravenstijn, Paulien, Samtani, Mahesh, Russu, Alberto, Hough, David, Gopal, Srihari
Argitaratua izan da J Clin Psychopharmacol (2016)

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population

nork Russu, Alberto, Mathews, Maju, Savitz, Adam, Gopal, Srihari, Feng, Yu
Argitaratua izan da Int J Neuropsychopharmacol (2016)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to On...

nork O’Donnell, Amy, Rao, Sanjai, Turkoz, Ibrahim, Gopal, Srihari, Kim, Edward
Argitaratua izan da Neuropsychiatr Dis Treat (2021)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

nork Gopal, Srihari, Liu, Yanning, Alphs, Larry, Savitz, Adam, Nuamah, Isaac, Hough, David
Argitaratua 2013

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY

nork Mathews, Maju, Gopal, Srihari, Singh, Arun, Gogate, Jagadish, Kim, Edward, Pungor, Katalin
Argitaratua izan da Schizophr Bull (2018)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

nork Gopal, Srihari, Gogate, Jagadish, Pungor, Katalin, Kim, Edward, Singh, Arun, Mathews, Maju
Argitaratua izan da Neuropsychiatr Dis Treat (2020)

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies

nork Markowitz, Michael, Fu, Dong-Jing, Levitan, Bennett, Gopal, Srihari, Turkoz, Ibrahim, Alphs, Larry
Argitaratua 2013

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia

nork Levitan, Bennett, Markowitz, Michael, Turkoz, Ibrahim, Fu, Dong-Jing, Gopal, Srihari, Alphs, Larry
Argitaratua izan da Int Clin Psychopharmacol (2016)

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, doub...

nork Savitz, Adam J., Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Mathews, Maju, Soares, Bernardo
Argitaratua izan da Braz J Psychiatry (2019)

A Post-hoc Comparison of Paliperidone Palmitate to Oral Risperidone During Initiation of Long-acting Risperidone Injection in Patients with Acute Schizophrenia

nork Gopal, Srihari, Pandina, Gahan, Lane, Rosanne, Nuamah, Isaac, Remmerie, Bart, Coppola, Danielle, Hough, David
Argitaratua 2011

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose

nork Samtani, Mahesh N, Nuamah, Isaac, Gopal, Srihari, Remmerie, Bart, Kern Sliwa, Jennifer, Alphs, Larry
Argitaratua 2013

Comparing Injection Site Pain with Paliperidone Palmitate Versus First-Generation Depot Antipsychotics in Subjects with Schizophrenia

nork Gopal, Srihari, Palermo, Teresa, Sliwa, Jennifer Kern, Nuamah, Isaac, Fu, Dong-Jing, Alphs, Larry
Argitaratua izan da Innov Clin Neurosci (2015)

PM532. Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia

nork Savitz, Adam, Haiyan, Xu, Gopal, Srihari, Nuamah, Isaac, Hough, David, Mathews, Maju, Feng, Yu
Argitaratua izan da Int J Neuropsychopharmacol (2016)

PM410. Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophreni...

nork Mathews, Maju, Nuamah, Isaac, Savitz, Adam, Hough, David, Najarian, Dean, Kim, Edward, Gopal, Srihari
Argitaratua izan da Int J Neuropsychopharmacol (2016)

Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study

nork Kane, John M., Correll, Christoph U., Delva, Nicholas, Gopal, Srihari, Savitz, Adam, Mathews, Maju
Argitaratua izan da J Clin Psychopharmacol (2019)

S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A...

nork Blackwood, Clifton, Sanga, Panna, Nuamah, Isaac, Keenan, Alexander, Singh, Arun, Mathews, Maju, Gopal, Srihari
Argitaratua izan da Schizophr Bull (2020)

Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

nork Blackwood, Clifton, Sanga, Panna, Nuamah, Isaac, Keenan, Alexander, Singh, Arun, Mathews, Maju, Gopal, Srihari
Argitaratua izan da Patient Prefer Adherence (2020)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia

nork Lambert, Martin, Sanchez, Pedro, Bergmans, Paul, Gopal, Srihari, Mathews, Maju, Wooller, Annette, Pungor, Katalin
Argitaratua izan da Neuropsychiatr Dis Treat (2020)